explore -WSS

explore

author：knowledge 2025-08-04 12:32:06 - browse：3

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Methadone treatment changes are coming. Do they go far enough?

knowledge

WSS

Health AI adoption puts security, privacy startups on investors' radar

Biden praises World Series champion Astros for impact off the field during White House celebration

Intermittent fasting comes with a heart risk? Not so fast

Hospitals use virtual reality to design more inclusive rooms for kids

Asbestos, a deadly carcinogen, banned by EPA

CVS Caremark has created a new ploy: the drug ‘rebate credit’

focus

explore

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ohioans vote in high

Virginia high school admissions case could be legal follow

Choosing scientific sides in the fight against Alzheimer's

After affirmative action ruling, medical educators look to 'holistic review'

Stop the failed accountable care organization experiment

Trump demands the U.S. pay no more for drugs than other countries … again

CDC launches VaccineFinder tool to locate Covid

Walensky prepares to leave CDC — and Congress — behind

Argenx readies a blockbuster opportunity with drug for autoimmune disease

knowledge

Nurses recount patients attacks

Biden praises World Series champion Astros for impact off the field during White House celebration

Orchard's therapy for neuron disease in children wins FDA approval

Sage's campaign to raise awareness of postpartum depression hits a nerve

‘The Bear’ and hospitality in hospitals

In venture capital firm's success, lessons for turning crisis into profit

Wikipedia

hotspot

knowledge

entertainment